A detailed history of Ifm Investors Pty LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ifm Investors Pty LTD holds 435,849 shares of BMY stock, worth $25.7 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
435,849
Previous 441,577 1.3%
Holding current value
$25.7 Million
Previous $18.3 Million 23.0%
% of portfolio
0.22%
Previous 0.19%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$39.66 - $51.75 $227,172 - $296,424
-5,728 Reduced 1.3%
435,849 $22.6 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $36,788 - $48,432
914 Added 0.21%
441,577 $18.3 Million
Q1 2024

Apr 22, 2024

SELL
$47.98 - $54.4 $286,968 - $325,366
-5,981 Reduced 1.34%
440,663 $23.9 Million
Q4 2023

Jan 12, 2024

SELL
$48.48 - $57.85 $111,358 - $132,881
-2,297 Reduced 0.51%
446,644 $22.9 Million
Q3 2023

Oct 26, 2023

BUY
$57.89 - $64.73 $779,778 - $871,913
13,470 Added 3.09%
448,941 $26.1 Million
Q2 2023

Jul 27, 2023

BUY
$63.71 - $70.74 $984,000 - $1.09 Million
15,445 Added 3.68%
435,471 $27.8 Million
Q1 2023

May 11, 2023

BUY
$65.71 - $74.53 $676,484 - $767,286
10,295 Added 2.51%
420,026 $29.1 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $2.12 Million - $2.51 Million
30,923 Added 8.16%
409,731 $29.5 Million
Q3 2022

Oct 12, 2022

BUY
$0.13 - $76.84 $415 - $245,734
3,198 Added 0.85%
378,808 $26.9 Million
Q2 2022

Jul 15, 2022

BUY
$72.62 - $79.98 $1.23 Million - $1.36 Million
16,978 Added 4.73%
375,610 $28.9 Million
Q1 2022

Apr 13, 2022

BUY
$61.48 - $73.72 $3.41 Million - $4.09 Million
55,413 Added 18.27%
358,632 $26.2 Million
Q4 2021

Jan 18, 2022

SELL
$53.63 - $62.52 $41,670 - $48,578
-777 Reduced 0.26%
303,219 $18.9 Million
Q3 2021

Oct 13, 2021

BUY
$59.17 - $69.31 $8,165 - $9,564
138 Added 0.05%
303,996 $18 Million
Q2 2021

Jul 16, 2021

BUY
$61.91 - $67.42 $3.27 Million - $3.56 Million
52,809 Added 21.04%
303,858 $20.3 Million
Q1 2021

May 05, 2021

BUY
$59.34 - $66.74 $1.9 Million - $2.14 Million
32,032 Added 14.63%
251,049 $15.8 Million
Q4 2020

Jan 13, 2021

BUY
$57.74 - $65.43 $1.77 Million - $2.01 Million
30,652 Added 16.27%
219,017 $13.6 Million
Q3 2020

Oct 16, 2020

BUY
$57.43 - $63.64 $1.19 Million - $1.32 Million
20,751 Added 12.38%
188,365 $11.4 Million
Q2 2020

Jul 13, 2020

SELL
$54.82 - $64.09 $3.61 Million - $4.21 Million
-65,762 Reduced 28.18%
167,614 $9.86 Million
Q1 2020

Apr 09, 2020

SELL
$46.4 - $67.43 $360,156 - $523,391
-7,762 Reduced 3.22%
233,376 $12.7 Million
Q4 2019

Jan 13, 2020

BUY
$49.21 - $64.19 $3.18 Million - $4.15 Million
64,607 Added 36.6%
241,138 $15.5 Million
Q3 2019

Nov 01, 2019

BUY
$42.77 - $50.71 $2.61 Million - $3.09 Million
61,021 Added 52.83%
176,531 $8.95 Million
Q2 2019

Jul 16, 2019

BUY
$44.62 - $49.34 $378,288 - $418,304
8,478 Added 7.92%
115,510 $5.24 Million
Q1 2019

Apr 18, 2019

BUY
$45.12 - $53.8 $574,693 - $685,250
12,737 Added 13.51%
107,032 $5.11 Million
Q4 2018

Jan 23, 2019

BUY
$48.76 - $63.23 $396,857 - $514,628
8,139 Added 9.45%
94,295 $4.9 Million
Q3 2018

Oct 22, 2018

BUY
$55.19 - $62.25 $678,616 - $765,426
12,296 Added 16.65%
86,156 $5.35 Million
Q2 2018

Jul 09, 2018

BUY
$50.53 - $62.98 $1.16 Million - $1.44 Million
22,871 Added 44.85%
73,860 $4.09 Million
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $296,963 - $341,864
4,956 Added 10.77%
50,989 $3.23 Million
Q4 2017

Jan 29, 2018

SELL
$59.94 - $65.35 $18,761 - $20,454
-313 Reduced 0.68%
46,033 $2.82 Million
Q3 2017

Nov 16, 2017

BUY
$55.23 - $63.74 $40,317 - $46,530
730 Added 1.6%
46,346 $2.95 Million
Q2 2017

Aug 10, 2017

BUY
N/A
11,796 Added 34.88%
45,616 $2.54 Million
Q1 2017

Aug 17, 2017

BUY
N/A
33,820
33,820 $1.84 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ifm Investors Pty LTD Portfolio

Follow Ifm Investors Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifm Investors Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Ifm Investors Pty LTD with notifications on news.